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In this study, we examined the importance of membrane ergosterol and sphingolipids in the drug suscep-
tibilities of Candida albicans. We used three independent methods to test the drug susceptibilities of erg mutant
cells, which were defective in ergosterol biosynthesis. While spot and filter disk assays revealed that erg2 and
erg16 mutant cells of C. albicans became hypersensitive to almost all of the drugs tested (i.e., 4-nitroquinoline
oxide, terbinafine, o-phenanthroline, itraconazole, and ketoconazole), determination of the MIC at which 80%
of the cells were inhibited revealed more than fourfold increase in susceptibility to ketoconazole and terbin-
afine. Treatment of wild-type C. albicans cells with fumonisin B1 resulted in 45% inhibition of sphingolipid
biosynthesis and caused cells to become hypersensitive to the above drugs. Although erg mutants displayed
enhanced membrane fluidity and passive diffusion, these changes alone were not sufficient to elicit the observed
hypersusceptibility phenotype of erg mutants. For example, the induction in vitro of a 12% change in the
membrane fluidity of C. albicans cells by a membrane fluidizer, benzyl alcohol, did not affect the drug
susceptibilities of Candida cells. Additionally, the surface localization of green fluorescent protein-tagged
Cdr1p, a major drug efflux pump protein of C. albicans, revealed that any disruption in ergosterol and
sphingolipid interactions also interfered with its proper surface localization and functioning. A 50% reduction
in the efflux of the Cdr1p substrate, rhodamine 6G, in erg mutant cells or in cells with a reduced sphingolipid
content suggested a strong correlation between these membrane lipid components and this major efflux pump
protein. Taken together, the results of our study demonstrate for the first time that there is an interaction
between membrane ergosterol and sphingolipids, that a reduction in the content of either of these two
components results in a disruption of this interaction, and that this disruption has deleterious effects on the
drug susceptibilities of C. albicans cells.
Candida albicans is an opportunistic diploid fungus that
causes infection in immunocompromised and debilitated pa-
tients (30). The widespread and prolonged usage of azoles in
recent years has led to the rapid development of the phenom-
enon of azole resistance, which poses a major threat to anti-
fungal therapy (27, 46). Various mechanisms which contribute
to the development of azole resistance in Candida have been
implicated; these include the overexpression of or mutations in
the target enzyme of the azoles, lanosterol 14-demethylase, as
well as the overexpression of genes encoding drug efflux pumps
belonging to the ATP-binding cassette (ABC) superfamily,
namely, CDR1 and CDR2, and transporters belonging to the
major facilitator superfamily (MFS), namely, MDR1 (1, 10, 11,
16, 30, 31, 45).
It has been shown by various investigators that the action of
antifungal agents is modulated by subtle modification of the
membrane lipid composition (14, 16, 22, 28). Of note is that
clinical as well as adapted azole-resistant isolates of C. albicans
exhibit altered membrane phospholipid and sterol composi-
tions (16, 22). Among various classes of yeast lipids, membrane
sterol, which is also the target of azoles, is one of the important
constituents; it is responsible mainly for rigidity, stability, and
resistance to physical stresses (32). Therefore, a loss of sterol
generally results in destabilization of the membrane, leading to
increased membrane permeability and altered drug suscepti-
bilities of yeast cells (28, 32). The sphingolipids of C. albicans
are another class of important membrane lipid components;
they differ from those of mammalian cells in that they are
structurally less complex and contain phosphatidylinositol as
part of their polar head groups (6, 20). These observations
acquire significance when one considers recent reports which
show the existence of discrete membrane microdomains,
known as lipid rafts and composed predominantly of sphingo-
lipid and sterol, within lipid bilayers (4, 5, 19, 26, 37, 38, 48).
Interestingly, the up-regulation of lipids and proteins that con-
stitute lipid rafts and the caveolar membrane has been ob-
served in drug-resistant mammalian cells (18, 19). Addition-
ally, it was recently reported that human P glycoprotein/
multidrug resistance protein (Pgp/MDR1), which is a
homologue of ABC drug transporter Cdr1p of C. albicans, is
localized predominantly in cholesterol-enriched membrane
domains, and that the depletion of cholesterol impairs human
Pgp/MDR1-mediated drug transport (5, 23). Taken together,
these findings suggest that sphingolipids and sterol as individ-
ual components as well as their mutual interactions play an
important role in the functioning of the ABC drug efflux pump
proteins (9, 13, 19, 21, 35).
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In order to explore the interactions between sphingolipids
and ergosterol (a substitute for mammalian sterol) and their
involvement in the drug resistance of C. albicans, we exploited
two sets of conditions in this study. We used erg mutants of C.
albicans, which were deficient in ergosterol content, and we
also used C. albicans cells with reduced sphingolipid content
resulting from a selective blockage of sphingolipid synthesis.
We observed that a reduction in either of these two major
membrane lipid constituents had deleterious effects on drug
resistance, in that Candida cells became hypersensitive to most
of the drugs tested. Our results further suggest that ergosterol-
sphingolipid interactions are important determinants of the
surface localization of the major drug extrusion pump protein
Cdr1p, which in turn affects the drug susceptibilities of C.
albicans cells.
MATERIALS AND METHODS
Materials. Media chemicals were obtained from Difco (Detroit, Mich.) and
HiMedia (Mumbai, India), and lipid N-rhodamine-dioleoyl-phosphatidylethano-
lamine was purchased from Avanti Polar Lipids, Inc. (Albaster, Ala). L-Dipalmi-
toyl-phosphatidylcholine, poly-D-lysine, rhodamine 6G (R6G), the fluorescent
probe 1,6-diphenyl-1,3,5-hexatriene (DPH), and the drugs o-phenanthroline,
4-nitroquinoline oxide, terbinafine, and filipin were obtained from Sigma Chem-
ical Co. (St. Louis, Mo.). Fluconazole was provided by Ranbaxy Laboratories
(New Delhi, India), and ketoconazole and itraconazole were provided by Dupont
(Wilmington, Del.). 3H-labeled fluconazole was custom prepared by Amersham
Biosciences, Little Chalfont, United Kingdom. 1,1-dilinoleyl-3,3,3,3-tetra-
methylindocarbocyanine, 4-chlorobenzenesulfonate (FAST-DiI), and labeled
6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminohexanoyl] spingosylphosphocholine
(NBD-sphingomyelin [NBD-SM]) were purchased from Molecular Probes (Eu-
gene, Oreg.).
Yeast strains and growth media. C. albicans strains ATCC 44829 (wild type, 33
ERG ade), ATCC 44830 (erg16 ade), and ATCC 44831 (erg2 ade) were
procured from the American Type Culture Collection. The strains were main-
tained as described previously (2). The Saccharomyces cerevisiae strain used was
PSCDR1-GFP (an AD1-8u derivative expressing Cdr1p-green fluorescent pro-
tein [GFP]) (36). The yeast strain was cultured in YEPD broth (Bio 101, Vista,
Calif.) or SD-URA medium (Bio 101).
Drug susceptibility testing of C. albicans strains. Drug susceptibilities were
measured by using microtiter plate, spot, and filter disk assays. The MICs for the
strains were determined with a broth microdilution method as described previ-
ously (28). For the spot assay, 5-l samples of fivefold serial dilutions of each
yeast culture (each with cells suspended in normal saline to an optical density at
600 nm [OD600] of 0.1) were spotted onto YEPD plates in the absence (control)
or in the presence of the following drugs: 4-nitroquinoline oxide (0.1 g/ml),
terbinafine (0.4 g/ml), o-phenanthroline (4 g/ml), fluconazole (0.4 g/ml),
itraconazole (0.1 g/ml), and ketoconazole (0.02 g/ml). Growth differences
were recorded following incubation of the plates for 48 h at 30°C. The filter disk
assay was done as described earlier (28); the following drugs were spotted in a
volume of 5 to 10 l: 4-nitroquinoline oxide (3 g), terbinafine (16 g), o-
phenanthroline (64 g), fluconazole (32 g), itraconazole (20 g), and ketocon-
azole (2 g).
Labeling of spheroplasts for experiments involving fluorescence recovery after
photobleaching (FRAP). Spheroplasts were suspended at a density of 108 cells/ml
in 1 M sorbitol–0.1 M EDTA buffer and labeled with FAST-DiI. Labeling was
carried out by using a final concentration of 10 M FAST-DiI with 2% residual
ethanol in glass tubes in the dark for 30 min at 25°C with mild shaking. The final
pellet of spheroplasts was resuspended in a small volume of 1 M sorbitol–0.1 M
EDTA buffer. One drop of this suspension was mounted between a glass slide
and a coverslip which had been previously coated with 0.1 mg of poly-D-lysine/ml.
The coverslip was sealed with nail enamel and placed inverted on the microscope
stage for FRAP experiments.
Fluorescence imaging of C. albicans spheroplasts. Spheroplasts labeled with
FAST-DiI were imaged at a magnification of 100 with a 1.35 NA oil immersion
objective under the fluorescein filter set on an Olympus fluorescence microscope
equipped with a charge-coupled device camera (Cool SNAP-Pro) driven by
Image-Pro PLUS software. The FRAP experiments were performed in the
Gaussian spot-photobleaching and line-scanning mode on a Meridian Ultima
570 confocal laser scanning microscope. Recovery plots were analyzed by non-
linear regression and data were represented graphically by using Meridian Ul-
tima software version 4.15. Fluorescence recovery profiles and diffusion coeffi-
cients were analyzed as described by Koppel et al. (17).
FIG. 1. Drug resistance profiles of C. albicans wild-type (WT) and erg mutant cells determined by a spot assay as described earlier (28). For
this assay, 5-l samples of fivefold serial dilutions of each yeast culture (each with cells suspended in normal saline to an OD600 of 0.1) were spotted
on YEPD plates in the absence (control) or in the presence of 4-nitroquinoline oxide (0.1 g/ml), terbinafine (0.4 g/ml), o-phenanthroline (4
g/ml), fluconazole (0.4 g/ml), itraconazole (0.1 g/ml), and ketoconazole (0.02 g/ml).
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Fluorescence polarization studies. Steady-state fluorescence polarization stud-
ies of C. albicans cells with the fluorescent probe DPH were carried out essen-
tially as described earlier (28).
Drug diffusion and efflux assays. (i) Passive diffusion. Passive diffusion of the
fluorescent compound R6G and 3H-labeled fluconazole was determined by using
a previously described protocol (28).
(ii) R6G efflux. The functionality of Cdr1p was checked by assaying the energy-
dependent efflux of R6G, a known substrate of this drug extrusion pump protein.
The protocol for the efflux assay was described previously (16).
Labeling of cells with NBD-SM. Labeling of cells with NBD-SM was carried
out essentially as described earlier (28).
Estimation of sphingolipid synthesis. The assay for sphingolipid synthesis was
carried out as described by Mandala et al. (25).
RESULTS
erg mutants of C. albicans are susceptible to various drugs.
C. albicans mutants defective in ergosterol biosynthesis were
isolated earlier by Pesti et al. (33). These mutants were ex-
ploited in this study to examine whether the reduction in er-
gosterol levels in any way affects the drug susceptibilities of C.
albicans cells. As a first step, the lack of ergosterol in erg
mutant cells was confirmed by reverse-phase high-pressure liq-
uid chromatography (HPLC) and spectroscopic methods (data
not shown). We used three independent methods (spot, mi-
crotiter plate, and filter disk assays) to examine the drug sus-
ceptibilities of erg mutant cells (Fig. 1 and Tables 1 and 2).
We observed that in spot assays, the mutants showed in-
creased susceptibilities to 4-nitroquinoline oxide, terbinafine,
o-phenanthroline, itraconazole, and ketoconazole; however,
data on the MICs at which 80% of the cells were inhibited
(MIC80) (Table 1) showed that the erg mutants were hyper-
sensitive only to terbinafine and ketoconazole (more than two-
fold). In order to further confirm the susceptibilities of the erg
mutants, we measured the zones of inhibition obtained in filter
disk assays. As shown in Table 2, filter disk assays confirmed
the finding of the spot assays (Fig. 1) that erg mutants of C.
albicans were hypersensitive to all of the drugs tested, with the
exception of fluconazole. These results emphasize that varia-
tions between drug susceptibility assays can exist (8) and that
multiple drug susceptibility assays therefore should be used for
exact assessment. Of note is that when equal number of cells
were spotted on YEPD plates in the absence of drugs, erg
mutant cells were found to grow relatively slowly, but this
minor difference in growth rates did not affect the conclusions
with regard to their susceptibilities to drugs. The difference in
the rates of growth of erg mutant cells with or without drugs
was very distinct, clearly indicating that erg mutant cells were
TABLE 1. Drug resistance profiles for C. albicans strains, as
determined by a microtiter assay
Drug
MIC80 (g ml1) for the following
strain:
Wild
type erg2 erg16
4-Nitroquinoline oxide 0.5 0.25 0.25
Terbinafine 2 0.25 0.25
o-Phenanthroline 16 8 8
Fluconazole 0.5 0.5 0.25
Itraconazole 0.4 0.4 0.2
Ketoconazole 0.4 0.008 0.008
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hypersensitive, a finding which was also supported by the re-
sults of filter disk assays.
Membranes of erg mutants are more fluid. In order to as-
certain the change in membrane fluidity in erg mutants, we
used the FRAP technique, in which the lateral mobility of a
lipid probe (FAST-DiI) for C. albicans wild-type and erg mu-
tant strains was determined. The fluorescence distribution of
spheroplasts labeled with FAST-DiI is shown in Fig. 2A, panel
c; the same field is viewed under phase contrast in Fig. 2A,
panel b. There was no observable difference in the surface
fluorescence distributions of FAST-DiI between wild-type and
mutant strains (Fig. 2A, panels d [wild type], e [erg2], and f
[erg16]). Lateral mobility measurements for FAST-DiI on
spheroplasts labeled predominantly at the plasma membrane
(Fig. 2A, panels b and c) were analyzed as described by Koppel
et al. (17). Representative fluorescence recovery plots for C.
albicans wild-type and erg mutant strains are shown in Fig. 2B.
The absence of ergosterol in the C. albicans erg mutants was
accompanied by an increase in the diffusion coefficient of
FAST-DiI (Fig. 2C). The increases in the diffusion coefficient
of FAST-DiI and fluorescence polarization values (a decrease
in fluorescence polarization values implies higher fluidity)
demonstrate that erg mutants have more fluid membranes (Fig.
2C and D). Thus, the results of two independent fluidity mea-
surements confirm that the membranes of erg mutants of C.
albicans are more fluid.
erg mutants demonstrate enhanced passive diffusion of
drugs. The enhanced membrane fluidity of erg mutants could
affect passive diffusion, which could result in their hypersensi-
tivity to the drugs tested. This possibility was examined by
investigating passive drug diffusion into deenergized erg mu-
tant cells in which active transport was blocked. We used flu-
orescent R6G and 3H-labeled fluconazole as described previ-
ously (28) as probes to monitor passive diffusion. The R6G
distribution was determined by measuring the change in the
absorbance values for supernatants withdrawn at various times.
Figure 3A shows that both erg mutants had reduced concen-
trations of extracellular R6G in the supernatants over time.
These results imply that the passive diffusion of R6G is faster
in erg mutants than in the wild type. Similar results were ob-
tained when we used 3H-labeled fluconazole to monitor flu-
conazole accumulation in energy-depleted cells. It is apparent
from Fig. 3B that due to enhanced diffusion, the cells of both
erg mutants accumulated larger amounts of fluconazole than
did wild-type cells. The enhanced passive diffusion of R6G and
fluconazole by erg mutants indicates that the mutants are more
permeable, a property that could explain their hypersensitivity
to drugs.
In vitro-induced changes in membrane fluidity do not affect
drug resistance. In order to determine whether increased
membrane fluidity and permeability alone was responsible for
the altered drug susceptibilities observed in Candida erg mu-
tants, we manipulated the fluidity of membranes of wild-type
Candida cells in vitro by using a known membrane fluidizer,
benzyl alcohol (BA) (28, 34, 39). The addition of 25 mM BA
led to a 12% increase in the membrane fluidity of Candida
wild-type cells (Fig. 3C). However, this BA-induced change in
membrane fluidity did not alter susceptibilities to the drugs
tested (Fig. 3D). Note that the cause of fluidity changes in-
duced by BA is different from that observed in erg mutant cells.
Nonetheless, the two experiments suggest that changes in flu-
TABLE 2. Drug resistance profiles for C. albicans strains, as determined by a filter disk assay
Drug (g)a Wildtype erg2 erg16
Zone of inhibition (cm) for the following strain:
Wild
type erg2 erg16
4-Nitroquinoline oxide (3) 2.4 2.8 3.4
Terbinafine (16) 1.5 2.1 2.3
o-Phenanthroline (64) 1.5 2.2 2.4
Fluconazole (32) 1.0 1.1 1.2
Itraconazole (20) 2.1 2.4 2.7
Ketoconazole (2) 3.1 4.0 4.6
a Drugs were spotted at the indicated concentrations in a volume of 5 to 10 l.
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idity alone were not sufficient to cause the changes in drug
susceptibilities that we observed.
NBD-SM is readily exchangeable from erg mutants. In view
of the interactions of membrane sterol and sphingolipids, ob-
served particularly in membrane microdomains or rafts in
other organisms (3, 4), we attempted to explore the occurrence
of such interactions in the membrane of Candida cells. We
labeled Candida wild-type and erg mutant cells with fluorescent
NBD-SM as described earlier (28, 40). The main advantage of
this fluorescent lipid analogue is that it can be readily inserted
into biological membranes by spontaneous lipid exchange from
exogenous carriers (15, 40). Thus, at 90 min postlabeling, when
NBD-SM incorporation into the Candida membrane was
found to be at the maximum (data not shown), the cells were
washed and the NBD-SM of labeled cells was back extracted
with fatty acid-free bovine serum albumin (BSA). Figure 4
depicts the exchangeable NBD-SM from Candida wild-type
and mutant cells. It was apparent that the amount of NBD-SM
back extracted with BSA from erg mutant cells was much
higher than that from wild-type cells (Fig. 4). This finding
would mean that ergosterol depletion in erg mutant cells re-
sults in disruption of the interactions between ergosterol and
sphingomyelin and thereby leads to enhanced exchangeability
of sphinogomyelin. Interestingly, the exchange of NBD-SM
was considerably reduced (restored to the level in wild-type
cells) when erg mutant cells were grown in ergosterol-supple-
mented media (Fig. 4).
Drug susceptibilities of C. albicans cells are affected by fluc-
tuations in sphingolipid content. In order to explore whether
the drug susceptibilities of C. albicans cells are also affected by
membrane sphingolipid levels, we used fumonisin B1, an in-
hibitor of sphingolipid biosynthesis which blocks the formation
FIG. 3. (A) Extracellular R6G concentrations in C. albicans wild-type (F), erg2 (Œ), and erg16 () cells at various time intervals. Deenergized
C. albicans cells were incubated with R6G at 30°C. At various time points, cells were rapidly centrifuged, and the extracellular concentrations of
R6G in the supernatants were determined spectrophotometrically at 527 nm. The values are the means and standard deviations (indicated by bars)
of three independent experiments. (B) Accumulation of 3H-labeled fluconazole in deenergized C. albicans wild-type (F), erg2 (Œ), and erg16 ()
cells at various time intervals. (C) Measurements of steady-state fluorescence polarization of C. albicans wild-type cells in the absence (white bar)
or in the presence of 12.5 mM (gray bar) and 25 mM (black bar) concentrations of BA. Steady-state fluorescence polarization was determined by
using DPH as the probe as described in the legend to Fig. 2D. (D) Drug resistance profiles (microtiter assay) of C. albicans wild-type cells in the
absence (white bar) or in the presence of 12.5 mM (gray bar) and 25 mM (black bar) concentrations of BA. The MIC80 was determined as described
earlier (28). Abbreviations: Flu, fluconazole; Keto, ketoconazole; Itra, itraconazole; Terb, terbinafine; Nqo, 4-nitroquinoline oxide; and Phe,
o-phenanthroline.
FIG. 4. Postlabeling transbilayer exchange of NBD-SM in C. albi-
cans wild-type, erg2, and erg16 cells. Cells were grown in the absence
(white bars) or in the presence (gray bars) of medium supplemented
with 20 g of ergosterol/ml. Cells were labeled with NBD-SM and then
back extracted with 2% BSA as described in Results. The graph pre-
sents data for the 90-min time point, at which the maximum back-
extracted fluorescence in the supernatant was observed. The values are
the means and standard deviations (indicated by bars) of three inde-
pendent experiments.
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of phytoceramide from phytosphingosine and thus inhibits the
synthesis of the major sphingolipids (Fig. 5A). Wild-type C.
albicans cells grown in the presence of 50 and 100 M fumo-
nisin B1 had 45 and 55% reductions in sphingolipid synthesis,
respectively (data not shown). Interestingly, the reduction in
sphingolipid content due to the blockage of sphingolipid syn-
thesis by fumonisin B1 caused wild-type C. albicans cells to
become hypersensitive to most of the drugs tested (Fig. 5B).
The effect of fumonisin B1 on erg mutant drug susceptibilities
was variable. While erg2 mutant cells showed no further sig-
nificant change in drug susceptibilities in the presence of the
inhibitor, erg16 mutant cells showed even higher susceptibili-
ties to some of the drugs (Fig. 5B). Of note is that the ergos-
terol content and membrane fluidity of C. albicans in the pres-
ence of fumonisin B1 did not change significantly (data not
shown). Thus, the observed hypersensitivity of fumonisin B1-
treated wild-type cells to various drugs could be attributed
solely to reduced sphingolipid content. It appears that mem-
brane lipid constituents, particularly ergosterol and sphingo-
lipids, are able to independently affect the drug susceptibilities
of C. albicans cells. These observations acquire significance
when one considers the interactions between membrane sterol
and sphingolipids (discussed below).
Depletion of ergosterol or sphingolipids leads to poor sur-
face localization of GFP-tagged Cdr1p. It was observed earlier
that Cdr1p functioning was susceptible to the membrane lipid
environment and, particularly, that the depletion of ergosterol
had deleterious effects on drug susceptibilities (28, 41). The
localization of Cdr1p in membrane rafts has not been unequiv-
ocally established, but based on the interactions between er-
gosterol and sphingolipids (membrane raft components) and
their effects on drug susceptibilities, it is very likely that Cdr1p,
a drug transporter protein, is localized in such domains.
In order to examine whether the depletion of ergosterol or
sphingolipids would in any way affect the surface localization of
Cdr1p and thus in turn its functioning, we used an S. cerevisiae
expression system that was developed by Nakamura et al. (29)
and that was a generous gift from R. D. Cannon, University of
Otago, Dunedin, New Zealand. AD1-8u, from which seven
major ABC transporters have been deleted, was derived from
a pdr1-3 mutant strain that causes hyperinduction of the PDR5
promoter. We achieved a high level of expression of Cdr1p-
GFP by integrating the Cdr1p-GFP open reading frame at the
PDR5 locus downstream from the PDR5 promoter in strain
AD1-8u; the resulting strain was designated PSCDR1-GFP
(36).
Figure 6A shows confocal images of S. cerevisiae cells in
which Cdr1p is overexpressed as a GFP-tagged protein. It is
evident that Cdr1p is localized on the plasma membrane.
Upon treatment with 50 M fumonisin B1 (Fig. 6B), however,
FIG. 5. (A) Schematic representation of the yeast sphingolipid biosynthesis pathway. Fumonisin B1 inhibits the formation of phytoceramide
from phytosphingosine. (B) Microtiter assays (MIC80s) of C. albicans wild-type (WT) and erg mutant cells in the absence or in the presence of 50
M fumonisin B1 (FumB1) were carried out essentially as described earlier (28).
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the GFP fluorescence appeared to be concentrated inside the
cells, implying poor surface localization of Cdr1p. Incubation
with the polyene antibiotic filipin for an extended period of
time was shown earlier to induce deformations and distortions
in sterol-containing membranes (7, 12, 44) because filipin is
known to interact with the 3--hydroxyl group of sterols. To
examine whether filipin-induced distortions would in any way
affect Cdr1p localization, we checked the localization of the
GFP-tagged protein by confocal microscopy after extended
incubation of the cells with filipin. Figure 6C shows that the
surface localization of Cdr1p was affected by extended filipin
treatment and that this mislocalization was comparable to that
seen in fumonisin B1-treated cells (Fig. 6B). It is apparent that
the disruption in vitro of interactions between ergosterol and
sphingolipids by either filipin or fumonisin B1 results in im-
proper surface localization of Cdr1p.
Sphingolipid and ergosterol depletion results in reduced
efflux of R6G. Since the surface localization of Cdr1p appeared
to be defective in cells in which interactions between ergosterol
and sphingolipids were disrupted, we examined the function-
ality of this drug extrusion pump by measuring the efflux of
R6G. R6G is a known substrate of Cdr1p and was used earlier
to monitor the drug efflux activity of this drug transporter (16,
24). R6G was allowed to enter deenergized Candida cells by
passive diffusion. The energy-dependent extrusion of R6G
then was initiated by the addition of glucose. The concentra-
tion of extruded dye in the supernatant was measured by mon-
itoring its absorbance at 527 nm. It is apparent from Fig. 7A
that the concentration of extruded R6G in the supernatant was
lower in both erg mutants than in the wild type. Similar results
FIG. 6. Phase-contrast imaging (left panels) and fluorescence imaging (middle panels) under a confocal microscope of strain PSCDR1-GFP
(A), strain PSCDR1-GFP grown in the presence of 50 M fumonisin B1 (Fum B1) (B), and strain PSCDR1-GFP incubated with 5 g of filipin/ml
for 2 h (C). Cells were grown overnight and viewed directly for GFP fluorescence on a glass slide under a 100 oil immersion objective in a
Radiance 2100 (AGR3Q/BLD; Bio-Rad) confocal microscope equipped with 488-nm excitation and 500- to 530-nm band-pass emission filters. The
fluorescence signal from strain PSCDR1-GFP showed the localization of Cdr1p on the plasma membrane. On treatment with Fum B1 or extended
incubation with filipin, the GFP fluorescence from strain PSCDR1-GFP appeared to be concentrated inside the cells, indicating poor surface
localization of Cdr1p. The right panels show the merge of the left and middle panels.
FIG. 7. Glucose-induced R6G efflux from C. albicans cells. Deen-
ergized cells were incubated with R6G for 2 h. Efflux was initiated by
the addition of 2% glucose, and the concentration of the extruded dye
in the supernatant was measured spectrophotometrically at 527 nm.
R6G efflux is represented as the extracellular concentration of R6G in
the supernatant 60 min after the addition of glucose to wild-type and
erg mutant cells (A) and to wild-type cells with or without treatment
with the indicated concentrations of fumonisin B1 (Fum B1) (B). The
values are the means and standard deviations (indicated by bars) of
three independent experiments.
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were obtained when we examined R6G efflux in wild-type cells
treated with various concentrations of fumonisin B1 (Fig. 7B).
The inhibitor-treated cells showed much less dye in the super-
natant, suggesting reduced Cdr1p-mediated efflux (Fig. 7B).
The results indicate that the disruption of interactions between
ergosterol and sphingolipids in the membrane results in re-
duced efflux activity of Cdr1p.
DISCUSSION
Our study demonstrates that C. albicans erg mutant cells,
which are defective in ergosterol synthesis, are hypersensitive
to drugs. The increased drug susceptibilities shown by the erg
mutant cells were not found to be merely due to an enhance-
ment in membrane fluidity and passive diffusion of drug mol-
ecules across the plasma membrane. Rather, the lack of ergos-
terol in the erg mutant cells, which disrupted or destabilized the
interactions within ergosterol-sphingolipid-rich microdomains,
was the main cause of the observed hypersensitivities of erg
mutant cells.
In support of the above conclusion, we observed a close
relationship between membrane ergosterol-sphingolipid inter-
actions and drug susceptibilities of C. albicans. We found that
a reduction in sphingolipid levels by the blockage of sphingo-
lipid synthesis also caused C. albicans cells to become hyper-
sensitive to various drugs. Further, the depletion of either one
of the membrane lipid components appeared to affect the
other. For example, we observed that erg mutants lacking er-
gosterol had larger amounts of exchangeable sphingolipids
than did the wild type (Fig. 4). Evidence that sphingolipid
content can affect the drug susceptibilities of yeast cells was
recently reported elsewhere (13). In that study, it was found
that IPT1 gene transcription was responsive to Pdr1p/Pdr3p
transcription factors that regulate pleiotropic drug resistance
genes of S. cerevisiae. The IPT1 gene encodes the last step of
sphingolipid biosynthesis, the loss of which has been shown to
have differential effects on drug resistance phenotypes. An
interaction between the two membrane lipid components was
also evident from several other independent studies in which
sphingolipid biosynthesis was shown to be coordinately regulated
with cholesterol metabolism in higher eukaryotes (42, 43, 47).
It is important to mention that human Pgp/MDR1 is pref-
erentially localized in microdomains (membrane rafts) rich in
cholesterol and sphingolipids in the plasma membrane of
mammalian cells and that its function is modulated by choles-
terol (23). Our observations that the multidrug ABC trans-
porter Cdr1p was poorly localized and that the efflux of the
fluorophore R6G was severely hampered in Candida cells
when interactions between ergosterol and sphingolipids were
disrupted suggest similar possibilities. It is thus tempting to
speculate that Cdr1p, a homologue of human Pgp, may also
preferentially reside within such membrane rafts, a possibility
which needs to be examined. In addition, the disruption of
interactions between the membrane lipid components proba-
bly results in the mislocalization of Cdr1p, which in turn affects
its functioning.
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